Sun Pharma Q2 FY27 profit drops 36% to ₹1,989 crore on one-time loss
Synopsis
Sun Pharma's headline profit fell 36% in Q2 FY27 — but strip out the ₹1,269 crore one-time charge and the story looks far healthier: double-digit revenue growth, a 17% India sales surge, and a rising domestic market share of 8.6%. Investors bought the dip, sending shares up nearly 4% on Friday.
Key Takeaways
Sun Pharma reported a 36.2 per cent YoY drop in net profit to ₹1,988.53 crore in Q2 FY27 due to a one-time exceptional loss of ₹1,269 crore .
Revenue from operations rose 11.9 per cent YoY to ₹16,198.71 crore , driven by strong domestic sales.
Excluding exceptional items, profit before tax grew 6.3 per cent to ₹4,428.2 crore .
India formulation sales surged 17.3 per cent to ₹5,552.3 crore ; domestic market share rose to 8.6 per cent .
US formulation sales declined 8.2 per cent to $455 million , remaining a drag on consolidated performance.
Shares rose 3.99 per cent to ₹1,833.30 on the BSE as investors focused on underlying operational strength.
Sun Pharmaceutical Industries Limited on 30 October 2026 reported a 36.2 per cent year-on-year decline in consolidated net profit to ₹1,988.53 crore for the second quarter of FY27 (July–September 2026), dragged down by a one-time exceptional loss of ₹1,269 crore. Despite the sharp headline hit, the country's largest drugmaker delivered double-digit revenue growth, signalling operational resilience beneath the accounting charge.
Revenue and Operating Performance
Revenue from operations climbed 11.9 per cent year-on-year to ₹16,198.71 crore in Q2 FY27, up from ₹14,478.31 crore in the same quarter a year earlier. At the operating level, earnings before interest, tax, depreciation and amortisation (EBITDA) rose 4.8 per cent to ₹4,744 crore from ₹4,527 crore, according to the company's regulatory filing. However, EBITDA margin contracted to 29.3 per cent from 31.3 per cent, reflecting cost pressures during the quarter. Excluding exceptional items, profit before tax stood at ₹4,428.2 crore, a 6.3 per cent increase over the year-ago period — a figure analysts are likely to treat as the cleaner read on underlying earnings.
India Business Drives Growth
Sun Pharma's domestic formulation segment remained a standout growth engine. India sales surged 17.3 per cent year-on-year to ₹5,552.3 crore from ₹4,735 crore, accounting for 34.5 per cent of consolidated revenue. The company's market share in the Indian pharmaceutical market expanded to 8.6 per cent from 8.3 per cent, according to the Pharmarack MAT September 2026 report — reinforcing its dominance in a market where branded generics continue to command premium pricing.
US Business Slides, Emerging Markets Hold Steady
In contrast, formulation sales in the United States fell 8.2 per cent to $455 million during the quarter, with the US business contributing approximately 27 per cent of total consolidated sales. Pricing pressure and generic competition in the American market have been persistent headwinds for Indian pharma majors. Emerging market formulation revenue grew a steadier 7.6 per cent year-on-year to $350 million, accounting for 20.7 per cent of consolidated sales, while rest-of-the-world markets posted 3.1 per cent growth to $241 million, contributing 14.3 per cent of total consolidated revenue.
R&D Investment and Market Reaction
Sun Pharma continued to allocate meaningfully toward innovation, with research and development expenditure reaching ₹778.4 crore — equivalent to 4.8 per cent of sales — during the quarter. Investors appeared to look past the headline profit decline; shares of Sun Pharma were trading 3.99 per cent higher at ₹1,833.30 per share on the BSE during noon trade on Friday, reflecting confidence in the company's underlying revenue trajectory and margin recovery potential.
With domestic momentum accelerating and R&D spend holding firm, the key question for the quarters ahead is whether Sun Pharma can stabilise its US business while sustaining double-digit India growth.
Point of View
But it obscures a more nuanced picture. Strip out the one-time charge and Sun Pharma is actually a company growing its top line at nearly 12 per cent and expanding domestic market share — not a small feat in a competitive generics landscape. The real concern is the US business, which shed 8.2 per cent and now contributes just 27 per cent of sales, down from historic highs. If pricing pressure in America deepens and the India growth engine eventually moderates, the company will need its R&D pipeline to deliver new specialty assets faster than the market expects.
NationPress
30 Oct 2026
Frequently Asked Questions
Why did Sun Pharma's profit fall in Q2 FY27?
Sun Pharma's net profit fell 36.2 per cent to ₹1,988.53 crore in Q2 FY27 primarily because of a one-time exceptional loss of ₹1,269 crore. Excluding this charge, profit before tax actually grew 6.3 per cent year-on-year to ₹4,428.2 crore.
How did Sun Pharma's revenue perform in Q2 FY27?
Revenue from operations grew 11.9 per cent year-on-year to ₹16,198.71 crore in the July–September 2026 quarter, up from ₹14,478.31 crore a year earlier. India formulation sales were the standout, rising 17.3 per cent.
What is Sun Pharma's market share in India?
According to the Pharmarack MAT September 2026 report, Sun Pharma's share in the Indian pharmaceutical market rose to 8.6 per cent from 8.3 per cent in the year-ago period. Domestic formulations now account for 34.5 per cent of consolidated sales.
Why did Sun Pharma's US business decline?
US formulation sales fell 8.2 per cent to $455 million in Q2 FY27, reflecting ongoing pricing pressure and generic competition in the American market — a challenge that has weighed on most large Indian pharma exporters. The US segment contributed approximately 27 per cent of total consolidated sales.
How did Sun Pharma shares react to the Q2 results?
Shares of Sun Pharma traded 3.99 per cent higher at ₹1,833.30 on the BSE during noon trade on 30 October 2026, as investors focused on the company's strong revenue growth and underlying operational performance rather than the headline profit decline.
